A Prospective, Multi-center Phase II Study of Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Stem-cell Transplantation, in Chronic Lymphocytic Leukemia Which is Associated With 17p Deletion or is Refractory to Fludarabine

Trial Profile

A Prospective, Multi-center Phase II Study of Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Stem-cell Transplantation, in Chronic Lymphocytic Leukemia Which is Associated With 17p Deletion or is Refractory to Fludarabine

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Dexamethasone; Pegfilgrastim
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 27 May 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register: DRKS00003930).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top